Atea Pharmaceuticals Inc. (AVIR)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
Atea Pharmaceuticals (AVIR) Upgraded to Buy: Here's What You Should Know
Atea Pharmaceuticals (AVIR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year?
Here is how Atea Pharmaceuticals, Inc. (AVIR) and Design Therapeutics, Inc. (DSGN) have performed compared to their sector so far this year.
Atea Pharmaceuticals: I'm Optimistic Ahead Of Critical HPV Catalyst
Atea Pharmaceuticals, Inc. receives a buy rating ahead of pivotal phase 3 BEM/RZR hepatitis C data expected mid-2026. AVIR's BEM/RZR targets a differentiated, short-duration, pan-genotypic HCV regimen, aiming for >95% sustained virologic response and low drug-drug interactions. AVIR's $256m cash runway extends through 2027, but commercial viability hinges on phase 3 success versus entrenched competitors Gilead and AbbVie.
Atea Pharmaceuticals Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 85 | $306 | $403.75 | $97.75 | 31.94% |
| BG Bart Gancher Intech Investment Management LLC | 16,840 | $53,307.2 | $79,646.46 | $26,339.26 | 49.41% |
 Point72 Asset Management LP Point72 Asset Management LP | 119,553 | $527,527.17 | $569,072.28 | $41,545.11 | 7.88% |
| YA Yinka Akinsola Blue Trust Inc. | 8,700 | $61,770 | $41,412 | -$20,358 | -32.96% |
 Joseph Castro Nuveen LLC | 243,103 | $732,889.56 | $1.17M | $434,004.84 | 59.22% |
Atea Pharmaceuticals Inc. (AVIR) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Atea Pharmaceuticals Inc. ever had a stock split?
Atea Pharmaceuticals Inc. Profile
| Biotechnology Industry | Healthcare Sector | Jean-Pierre Sommadossi CEO | NASDAQ (NGS) Exchange | 04683R106 CUSIP |
| US Country | 55 Employees | - Last Dividend | - Last Split | 30 Oct 2020 IPO Date |
Overview
Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that is deeply engaged in the discovery, development, and potential commercialization of antiviral therapeutics. Founded in 2012 and headquartered in Boston, Massachusetts, the company positions itself as a significant player in the pharmaceutical industry, focusing on the development of treatments for patients suffering from viral infections. Armed with a scientific approach and advanced research capabilities, Atea Pharmaceuticals aims to tackle some of the most pressing viral diseases facing humanity today, including COVID-19 and hepatitis C virus (HCV).
Products and Services
- AT-527:
- Bemnifosbuvir in combination with Ruzasvir:
- Protease Inhibitor for COVID-19:
- License agreement with MSD International GmbH for the development of Ruzasvir:
An oral antiviral candidate, currently in Phase 3 SUNRISE-3 clinical trial aimed at treating patients with COVID-19. AT-527 is designed to inhibit the replication of the SARS-CoV-2 virus, potentially providing a pivotal tool in managing the global pandemic. Its ease of administration and mechanism of action place it at the forefront of Atea Pharmaceuticals' product pipeline.
This combination therapy is in a Phase 2 clinical trial, targeting the treatment of the hepatitis C virus (HCV). This innovative approach combines bemnifosbuvir, an antiviral agent, with ruzasvir, an NS5A inhibitor, aiming to offer an effective treatment solution for HCV. The dual-action of these compounds potentially increases efficacy and lowers resistance, positioning it as an essential addition to the arsenal against HCV.
A promising protease inhibitor specifically developed for the treatment of COVID-19. Although details on the stage of the development process are not provided, this initiative underscores Atea Pharmaceuticals' commitment to combating the ongoing pandemic through diversified therapeutic strategies.
A strategic partnership that permits the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. This collaboration not only amplifies the capabilities of Atea Pharmaceuticals in addressing HCV but also enhances its portfolio of antiviral treatments through cooperation with established pharmaceutical entities.
